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Negative regulation of chemokine receptor signaling
and B-cell chemotaxis by p66Shc
L Patrussi1,3, N Capitani1,3, E Cannizzaro1, F Finetti1, OM Lucherini1, PG Pelicci2 and CT Baldari*,1
Shc (Src homology 2 domain containing) adaptors are ubiquitous components of the signaling pathways triggered by tyrosine
kinase-coupled receptors. In lymphocytes, similar to other cell types, the p52 and p66 isoforms of ShcA/Shc participate in a self-
limiting loop where p52Shc acts as a positive regulator of antigen receptor signaling by promoting Ras activation, whereas
p66Shc limits this activity by competitively inhibiting p52Shc. Based on the fact that many signaling mediators are shared by
antigen and chemokine receptors, including p52Shc, we have assessed the potential implication of p66Shc in the regulation of
B-cell responses to chemokines, focusing on the homing receptors CXCR4 (C-X-C chemokine receptor type 4) and CXCR5 (C-X-C
chemokine receptor type 5). The results identify p66Shc as a negative regulator of the chemotactic responses triggered by these
receptors, including adhesion, polarization and migration. We also provide evidence that this function is dependent on the ability
of p66Shc to interact with the chemokine receptors and promote the assembly of an inhibitory complex, which includes the
phosphatases SHP-1 (Src homology phosphatase-1) and SHIP-1 (SH2 domain-containing inositol 5’-phosphatase-1), that results
in impaired Vav-dependent reorganization of the actin cytoskeleton. This function maps to the phosphorylatable tyrosine
residues in the collagen homology 1 (CH1) domain. The results identify p66Shc as a negative regulator of B-cell chemotaxis and
suggest a role for this adaptor in the control of B-cell homing.
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Lymphocyte homeostasis and activation require their cyclic
traffic through the secondary lymphoid organs (SLOs).
Lymphocyte homing to SLOs, as well as their traffic therein,
is regulated by receptors that respond to stromal cell-derived
chemokines.1 The principal B-cell homing receptors are
CCR7 (C-C chemokine receptor type 7) and CXCR4 (C-X-C
chemokine receptor type 4) that are responsible for their
egress from the bloodstream and entry into the SLOs,2
whereas B-cell traffic to the follicles is regulated by CXCR5
(C-X-C chemokine receptor type 5).3 These receptors also
assist retaining B-cells in the SLOs that is essential for B-cells
to receive survival cues and become activated in the presence
of antigen.3
Chemokine receptors orchestrate the sequential steps of
lymphocyte homing, that is, arrest, polarization and transen-
dothelial migration, both by triggering the conversion of
integrins to their high-affinity conformation for their ligands
on endothelial cells (ECs), which results in firm adhesion, and
by promoting the cytoskeletal rearrangements required for
polarization and migration.4 Chemokine receptors are Gi-
protein-coupled seven-spanning transmembrane receptors
that reduce cyclic adenosine monophosphate (cAMP) pro-
duction by inhibiting adenylate cyclase.5 Src kinases partici-
pate in the Gi/cAMP-dependent pathways triggered by
chemokine receptors, initiating a phoshorylation cascade that
promotes both inside-out signaling to integrins and the Rho
GTPase-dependent cytoskeletal rearrangements required for
cell polarization and migration.6–8 Chemokine receptors also
trigger a Gi-independent, Janus kinase (JAK)-dependent
pathway implicated in cell migration.8 Hence, chemotaxis is
coordinately regulated by multiple signaling pathways.
At variance with T cells, where signaling by chemokine
receptors has been characterized to a significant extent,9 our
understanding of the signaling cascades triggered by homing
receptors in B-cells is remarkably limited, notwithstanding the
fact that some of the molecules implicated, such as spleen
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tyrosine kinase (Syk), phosphatidylinositide 3-kinase (PI3-K)
and Bruton’s tyrosine kinase (Btk), are exploited therapeuti-
cally for the treatment of B-cell neoplasms.10,11 In particular,
the role of the adaptors that couple proximal tyrosine kinases
(TKs) to downstream mediators in other B-cell signaling
pathways remains largely elusive.
Shc (Src homology 2 domain containing) adaptors have
been implicated in all central cellular processes, including
proliferation, differentiation, survival and motility.12 In lym-
phocytes, the p52 and p66 ShcA/Shc isoforms form a self-
limiting loop, with p52Shc positively regulating antigen
receptor (AgR) signaling and p66Shc acting as a competitive
inhibitor.12 Accordingly, mitogenic and survival responses to
AgR engagement are enhanced in p66Shc / mice, result-
ing in autoimmunity.13 Moreover, chronic lymphocytic leuke-
mia (CLL) B-cells have a defect in p66Shc expression that
contributes to their extended survival.14 Based on the fact that
many signalingmediators are shared by AgRs and chemokine
receptors, including p52Shc,15 here we have assessed the
potential implication of p66Shc in the regulation of B-cell
responses to chemokines. We show that p66Shc acts as a
negative regulator of all steps of the chemotactic responses
triggered by CXCR4 and CXCR5 by inhibiting Vav-dependent
actin cytoskeleton reorganization and provide insight into the
mechanism by which p66Shc uncouples these receptors from
Vav activation.
Results
p66Shc inhibits CXCR4- and CXCR5-dependent B-cell
adhesion and polarization. B-cell adhesion to ECs is
regulated by the integrins lymphocyte function-associated
antigen-1 (LFA-1), which interacts with intercellular adhesion
molecule-1 (ICAM-1), and very late antigen-4 (VLA-4), which
interacts with both VCAM-1 and the ECM component,
fibronectin (FN). The role of p66Shc in B-cell adhesion was
initially addressed in the p66Shc-deficient MEC B-cells,14
stably transfected with a p66Shc-encoding construct, using
empty vector-transfected cells as control. All transfectants
expressed similar levels of LFA-1 and VLA-4, as well as
CXCR4 and CXCR5 (Supplementary Figure S1A). Cells
were plated on immobilized ICAM-1 or FN in the presence or
absence of CXCL12 (C-X-C motif chemokine 12) or CXCL13
(C-X-C motif chemokine 13). The proportion of cells that had
adhered after a short incubation was determined by flow
cytometry. As expected, control cells underwent profound
morphological changes in the presence of either chemokine,
from a round to a polarized phenotype characterized by
F-actin-rich protrusions (Figure 1a). p66Shc expression
resulted in impaired CXCR4- and CXCR5-dependent adhe-
sion to ICAM-1/FN (Figure 1b). Consistent with this finding,
imaging of these cells showed that the punctate pattern of
LFA-1, which results from integrin clustering following the
high-affinity conformational shift,16 was lost in p66Shc-
expressing MEC cells (Supplementary Figure S2). Polariza-
tion was also impaired in the presence of p66Shc, as
assessed by quantitating phalloidin-stained cells harboring a
polarized morphology (Figures 1a and c).
Similar experiments were carried out on splenic B-cells
from wild-type and p66Shc / mice. CXCL12- and
CXCL13-dependent adhesion to ICAM-1/FN (Figure 1d), as
well as polarization (Figure 1e), were significantly enhanced in
p66Shc / B-cells compared with their wild-type counter-
parts, indicating that expression of p66Shc at physiological
levels is sufficient to negatively regulate the B-cell responses
to these chemokines. No difference was observed in the
expression levels of either LFA-1/VLA-4 or CXCR4/CXCR5
between wild-type and p66Shc / B-cells (Supplementary
Figure S1B). Hence, p66Shc acts as a negative regulator of
the inside-out pathways that couple CXCR4/CXCR5 to
integrin activation.
p66Shc inhibits CXCR4- and CXCR5-dependent B-cell
chemotaxis. The implication of p66Shc in B-cell chemotaxis
was addressed in transwell migration assays, using CXCL12/
CXCL13 as chemoattractants. Both CXCR4- and CXCR5-
dependent migration was impaired in p66Shc-expressing
MEC cells compared with controls (Figure 2a). Consistent
with this observation, migration of p66Shc / B-cells toward
CXCL12/CXCL13 was enhanced compared with wild-type
controls (Figure 2b).
The ability of p66Shc to affect chemotaxis was further
assessed in B-cell pseudoemperipolesis assays that measure
the ability of B-cells to migrate beneath co-cultured stromal
cells.17 Spontaneous emperipolesis was not affected by
p66Shc. At variance, p66Shc-expressing MEC cells under-
went CXCR4- and CXCR5-dependent pseudoemperipolesis
with a lower efficiency compared with controls (Figure 2c).
This defect was confirmed in co-culture experiments using a
mixture of control and p66Shc-expressing MEC cells labeled
with different fluorescent probes. Indeed, a smaller number of
p66Shc-expressing cells underwent pseudoemperipolesis
compared with controls within the same stromal cell layer
(Figure 2c). Consistent with these results, pseudoemperipolesis
was enhanced in p66Shc / B-cells compared with wild-type
B-cells (Figure 2d). Hence, p66Shc acts as a negative
regulator of CXCR4- and CXCR5-dependent B-cell migration.
p66Shc inhibits CXCR4- and CXCR5-dependent actin
polymerization and Vav activation. The ability of p66Shc
to affect B-cell polarization and migration in response to
CXCL12/CXCL13 suggests that it may be implicated in
coupling CXCR4/ CXCR5 to actin polymerization. This issue
was addressed by confocal microscopy of control and
p66Shc-expressing MEC cells plated on ICAM-1/FN in the
presence or absence of CXCL12 or CXCL13. Cells were
labeled with phalloidin to identify F-actin and anti-actin
monoclonal antibody (mAb) as normalization control. Mea-
surement of the F-actin fluorescence intensity showed that
p66Shc expression resulted in a significant impairment in
CXCR4- and CXCR5-dependent actin polymerization
(Figure 3a; not shown for FN). Similar experiments were
carried out on purified splenic wild-type and p66Shc /
B-cells. A more robust actin polymerization in response to
CXCL12/CXCL13 of p66Shc / B-cells plated on either
ICAM-1 (Figure 3b) or FN (not shown) was observed when
compared with wild-type B-cells, supporting a role for p66Shc
in coupling CXCR4/CXCR5 to actin polymerization.
Actin polymerization is orchestrated by Rho GTPases.18
Rac1 (Ras-related C3 botulinum toxin substrate 1) and Cdc42
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(cell division control protein 42 homolog) activation is depen-
dent on the guanine nucleotide exchanger, Vav, that is
activated by tyrosine phosphorylation and is moreover regu-
lated by PIP2/PIP3 (phosphatidylinositol 4,5-bisphosphate/
(3,4,5)-trisphosphate) binding to its pleckstrin homology (PH)
domain.19 Immunoblot analysis of Vav phosphorylation in the
MEC transfectants showed that p66Shc expression resulted
in an impairment in CXCR4- and CXCR5-dependent
Vav phosphorylation compared with controls (Figure 3c).
Phospho-Vav imaging in the control transfectant revealed an
enrichment of phospho-Vav in the F-actin-rich protrusions that
was not detectable in the presence of p66Shc (Figure 3d).
Hence, p66Shc modulates chemokine-dependent F-actin
reorganization by attenuating Vav activation.
p66Shc inhibits both the Src kinase- and the
PI3-K-dependent pathways triggered by CXCR4 and
CXCR5. Gi-proteins promote Vav activation through two
pathways activated respectively by the Gai and the Gbg
subunits.20,21 Gai activation results in a reduction in protein
kinase A (PKA) activity that reinforces the inhibitory loop
controlling Src kinases by enhancing the activity of C-term-
inal Src kinase (Csk).20 As a result, Lyn becomes activated
and initiates a phosphorylation cascade involving Syk and
Btk that together promote Vav phosphorylation.20 Gbg
promotes PI3-K activation22 that converges on Vav activation
by stabilizing at the plasma membrane of both Vav and
Btk through their PH domain-mediated interaction with
PIP2/PIP3.
21
To identify which of these pathways is regulated by
p66Shc, migration assays were carried out in the presence
of pharmacological inhibitors of chemokine receptor
signaling. As expected, treatment of control MEC cells
with pertussis toxin (PTX), a Gai inhibitor, or the phospho-
diesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX),
which neutralizes the effects of Gai, resulted in a block in
Figure 1 p66Shc inhibits CXCR4- and CXCR5-dependent, integrin-mediated B-cell adhesion and polarization. (a) Immunofluorescence analysis of control MEC
transfectants (ctr) plated on slides coated with 10 mg/ml rhICAM-1/Fc, either unstimulated or stimulated with 100 ng/ml CXCL12 or 200 ng/ml CXCL13, and labeled with
Phalloidin-TRITC (red) and anti-actin antibodies (green). Median optical sections are shown. Size bar, 5mm. (b, d) Quantification by flow cytometry of the percentage of ctr and
p66 stably transfected MEC cells (b) or of splenocytes from wt and p66Shc / mice (d) that adhered to 48-well plates coated with 10mg/ml rhICAM-1/Fc or 10mg/ml
Fibronectin following 10 min of treatment with either 100 ng/ml CXCL12 or 200 ng/ml CXCL13. Mouse cells were labeled with anti-CD3-FITC/anti-CD22-PE antibodies before
the analysis. The data, which refer to quadruplicate samples from four independent experiments, are presented as % of total input cells that remained attached to each well.
Error bars, S.D. *Pr0.05; **Pr0.01; ***Pr0.001. (c, e) Quantification of the percentage of polarized cells in the ctr and p66 MEC transfectants (c) or in B lymphocytes
purified from spleens of wt and p66Shc / mice (e) plated for 5 min on slides coated with either 10 mg/ml rhICAM-1/Fc or 10mg/ml Fibronectin stimulated for 5 min with either
100 ng/ml CXCL12 or 200 ng/ml CXCL13 and labeled with Phalloidin-TRITC and anti-actin antibodies. The percentage of polarized against not-polarized cells was calculated
on four different wide-field images from each well in three independent experiments. Error bars, S.D. *Pr0.05; **Pr0.01
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Figure 2 p66Shc inhibits CXCR4- and CXCR5-dependent B-cell chemotaxis. (a) Migration of ctr and p66 MEC transfectants, measured after treatment for 3 h with either
100 ng/ml CXCL12 or 200 ng/ml CXCL13. The data, obtained on duplicate samples from at least three independent experiments, are presented as mean migration
index±S.D. (ratio of migrated cells in chemokine-treated versus untreated samples). ***Pr0.001. An unrelated chemotactic stimulus (10 mM f-MLP) was used as a negative
control. No migration of either control or p66Shc-expressing MEC cells was observed in response to this treatment (data not shown). (b) Migration of cells obtained from
spleen, bone marrow or lymph nodes of wt and p66Shc / mice treated for 3 h with either 100 ng/ml mCXCL12 or 200 ng/ml mCXCL13 and then stained with anti-CD3-FITC/
anti-CD22-PE antibodies. The data, obtained on duplicate samples from at least three independent experiments, are presented as mean migration index±S.D. *Pr0.05;
**Pr0.01. (c and d) Quantification by flow cytometry of the percentage of ctr and p66 stably transfected MEC cells (c, lower panel) or of splenocytes from wt and p66Shc /
mice (d) that remained adherent to stromal cells grown on 48-well plates following stimulation with either 100 ng/ml CXCL12 or 200 ng/ml CXCL13. Before counting, MEC cells
were labeled with anti-CD19-FITC mAb and mouse cells with anti-CD3-FITC/anti-CD22-PE antibodies. The data, which refer to quadruplicate samples from at least four
independent experiments, are presented as % of total input cells that remained attached to each well. Error bars, S.D. *Pr0.05; **Pr0.01; ***Pr0.001. (c, upper panel).
Immunofluorescence analysis of ctr and p66 MEC transfectants stained respectively with DiO (green) or Dil (red) incubated for 10 min on stromal cells grown on 8-well slides
and either unstimulated or stimulated for 40 min with 100 ng/ml CXCL12 or 200 ng/ml CXCL13. Median optical sections are shown. Size bar, 5mm
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CXCR4/CXCR5-dependent migration (Figure 4a). Migration
was also inhibited by the Src kinase inhibitor PP2 and
the PI3-K inhibitor wortmannin (Figure 4a), as well
as the Jak inhibitor AG490 (Supplementary Figure S3).
The ability of p66Shc to attenuate CXCR4- and CXCR5-
dependent chemotaxis was further enhanced by PTX
and IBMX, as well as by PP2 and wortmannin (Figure 4a),
but not by AG490 (Supplementary Figure S3), indicating
that p66Shc selectively participates in the Src and PI3-K
pathways triggered by these receptors downstream of Gi
activation.
To map p66Shc in the Src-dependent pathway triggered by
CXCL12/CXCL13, phosphorylation of the initiating kinase Lyn
and the effector kinases Syk and Btk was measured by
immunoblot with phospho-specific antibodies. Lyn was
activated to a similar extent by CXCR4/CXCR5 engagement
in control and p66Shc-expressing MEC cells (Figure 4b).
Conversely, the chemokine-dependent activation of Syk and
Btk was significantly impaired in the presence of p66Shc
(Figure 4b), indicating that p66Shc participates in the TK-
dependent pathway triggered by CXCR4/CXCR5, attenuating
signaling downstream of Lyn.
Figure 3 p66Shc inhibits CXCR4- and CXCR5-dependent actin polymerization and Vav phosphorylation. (a and b) Quantification of actin polymerization in ctr and p66
MEC transfectants (a) or in B lymphocytes purified from spleens of wt and p66Shc / mice (b), plated for 5 min on slides coated with 10mg/ml rhICAM-1/Fc and stimulated
for 5 min with either 100 ng/ml CXCL12 or 200 ng/ml CXCL13. Slides were then labeled with Phalloidin-TRITC and anti-actin antibodies. The data, calculated on four different
wide-field images from four independent experiments, are presented as the mean fluorescence intensity (MFI) of Phalloidin staining in stimulated versus unstimulated
samples, quantitated using ImageJ software and normalized to the intracellular content of actin. Error bars, S.D. **Pr0.01; ***Pr0.001. (c) Immunoblot analysis with an
anti-phospho-Vav antibody of postnuclear supernatants from ctr and p66 MEC transfectants either unstimulated or stimulated for 1 or 5 min with 100 ng/ml CXCL12 (left)
or 200 ng/ml CXCL13 (right). Control anti-Vav immunoblots of the stripped filters are shown below. The migration of molecular mass markers is indicated. (d, right) Confocal
microscopic analysis of Vav phosphorylation in ctr and p66 MEC transfectants plated for 5 min on slides coated with 10mg/ml rhICAM-1/Fc and stimulated for 2 min with either
100 ng/ml CXCL12 or 200 ng/ml CXCL13. Slides were then labeled with anti-phospho-Vav and anti-Vav antibodies. Median optical sections are shown. Size bar, 5 mm. (d, left)
Quantification of Vav phosphorylation on four different wide-field images from three independent experiments presented as the MFI of phospho-Vav staining in stimulated
versus unstimulated samples, quantitated using ImageJ software and normalized to the intracellular content of Vav. Error bars, S.D. ***Pr0.001
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The implication of p66Shc in the PI3-K pathway triggered by
CXCL12/CXCL13 was also addressed, using as a readout a
PI3-K reporter encoding a green fluorescent protein (GFP)-
tagged PH domain. Confocal microscopy of control and
p66Shc-expressing MEC cells transiently transfected with the
PH-GFP construct showed that stimulation with CXCL12 or
CXCL13 resulted in a plasma membrane enrichment in
PH-GFP in control but not in p66Shc-expressing cells
(Figure 4c). Hence, p66Shc uncouples CXCR4/CXCR5
from Vav activation by impairing both TK-dependent and
phosphoinositide-dependent signaling.
Inhibition of CXCR4- and CXCR5-dependent signaling
by p66Shc requires phosphorylation of its CH1 domain.
The ability of p66Shc to modulate signaling depends on two
activities mapping to different domains of the protein. p66Shc
acts as an adaptor using the two phosphotyrosine-binding
domains and the proline-rich collagen homology 1 (CH1)
domain that recruits proteins through three phosphorylatable
tyrosine residues (YYY239/240/317). Moreover, p66Shc has
a pro-oxidant activity that maps both to a phosphorylatable
serine residue in the CH2 domain (S36) and to two glutamic
acid residues (EE132/133) in the cytochrome c binding
domain.12
To understand whether inhibition of CXCR4/CXCR5
signaling by p66Shc depends on its adaptor or its pro-oxidant
activity, we used a panel of MEC transfectants expressing
point mutants of p66Shc defective for these activities. These
included p66Shc3F (YYY239/240/317-FFF), p66ShcSA
(S36-A) and p66ShcQQ (EE132/133-QQ). These
mutants were expressed by the respective transfectants
at levels comparable to the wild-type protein in p66 MEC
Figure 4 p66Shc inhibits both Src kinase-dependent and PI3-K-dependent signaling in response to CXCL12 and CXCL13. (a) Migration of ctr and p66 MEC transfectants
untreated or treated for 2 h with either PP2 or 500 ng/ml PTX or 500mM IBMX or 100mM Wortmannin and then stimulated for 3 h with either 100 ng/ml CXCL12 (left) or 200 ng/ml
CXCL13 (right). The data, obtained on duplicate samples from at least three independent experiments, are presented as mean migration index±S.D. (ratio of migrated cells in
chemokine-treated versus untreated samples). *Pr0.05; **Pr0.01; ***Pr0.001. (b) Immunoblot analysis with anti-phospho-Lyn, anti-phospho-Syk or anti-phospho-Btk
antibodies of postnuclear supernatants from ctr and p66 MEC transfectants either unstimulated or stimulated for 1 min with 100 ng/ml CXCL12 or 200 ng/ml CXCL13. Control
immunoblots of the stripped filters are shown below. The migration of molecular mass markers is indicated. (c) Immunofluorescence analysis of ctr and p66 MEC cells
transiently transfected to express a PH-GFP fusion, immobilized 24 h after transfection on slides coated with 10 mg/ml rhICAM-1/Fc either unstimulated or stimulated with
100 ng/ml CXCL12 or 200 ng/ml CXCL13 and labeled with Phalloidin-TRITC (red) and anti-GFP antibodies (green). Median optical sections are shown. Size bar, 5mm.
A pharmacological CXCR4 antagonist (50 mM AMD3100, added 1 h before the chemokine) was used in combination with CXCL12 as a specificity control. No migration was
observed under these conditions in either control or p66Shc-expressing MEC cells (data not shown), consistent with the suppression under these conditions of all the signaling
cascades triggered by CXCR4 implicated in cell migration
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cells (Figure 5a). No differences were observed in the
expression of LFA-1, VLA-4, CXCR4 or CXCR5 compared
with control or p66Shc-expressing cells (Supplementary
Figure S1A).
Expression of the reactive oxygen species (ROS)-defective
mutants resulted in impaired B-cell migration and adhesion
compared with control cells, similar to p66Shc (Figure 5b
and Supplementary Figure S4A), ruling out a role for the
pro-oxidant activity of p66Shc in this function. Conversely, the
3F mutation reversed the ability of p66Shc to inhibit B-cell
chemotaxis (Figure 5b), as well as adhesion and polarization
(Figures 5c and d and Supplementary Figures S4A and B).
Accordingly, LFA-1 formed the typical punctate pattern
resulting from integrin clustering in p66Shc3F-expressing
cells (Supplementary Figure S2). The 3F mutation also fully
abrogated the ability of p66Shc to inhibit CXCR4/CXCR5-
dependent actin polymerization (Figure 5e and Supplementary
Figure S4C), Vav phosphorylation (Figure 6a) and
phospho-Vav enrichment in F-actin-rich protrusions
(Figure 6b and Supplementary Figure S4D). Moreover, no
defect in chemokine-dependent activation of Syk, Btk or PI3-K
(Figures 6c and d) was observed in p66Shc3F-expressing
Figure 5 Inhibition of CXCR4- and CXCR5-dependent adhesion and chemotaxis by p66Shc requires tyrosine phosphorylation of its CH1 domain. (a) Immunoblot analysis
of Shc expression in MEC B-cells stably transfected with empty vector (ctr) or an expression construct encoding either wild-type p66Shc (MEC p66) or the S36A (p66SA),
EE132/133QQ (p66QQ) or YYY239/240/317FFF (p663F) mutants. A control anti-actin blot of the stripped filter is shown below. The migration of molecular mass markers is
indicated. The domain structure of p66Shc showing the localization of the amino acid residues substituted in the mutants is schematized at the top of the panel. (b) Migration of
ctr, p66, p66SA, p66QQ and p663F MEC transfectants stimulated for 3 h with either 100 ng/ml CXCL12 (upper panel) or 200 ng/ml CXCL13 (lower panel). The data, obtained
on duplicate samples from at least three independent experiments, are presented as mean migration index±S.D. (ratio of migrated cells in chemokine-treated versus
untreated samples). ***Pr0.001. (c) Quantification by flow cytometry of the percentage of ctr, p66, and p663F cells that adhered to 48-well plates coated with 10 mg/ml
rhICAM-1/Fc following treatment with either 100 ng/ml CXCL12 or 200 ng/ml CXCL13 for 10 min. The data, which refer to quadruplicate samples from four independent
experiments, are presented as % of total input cells that remained attached to each well. Error bars, S.D. *Pr0.05; ***Pr0.001. Quantification of the percentage of
polarization (d) or actin polymerization (e) on ctr, p66 and p663F cells plated on slides coated with 10 mg/ml rhICAM-1/Fc, stimulated for 5 min with either 100 ng/ml CXCL12 or
200 ng/ml CXCL13 and labeled with Phalloidin-TRITC and anti-actin antibodies. The percentage of polarized cells (d) and the mean fluorescence intensity (MFI) of Phalloidin
staining in stimulated versus unstimulated samples (e) were calculated on four different wide-field images from each well in three independent experiments. Phalloidin staining
was quantitated using ImageJ software and normalized to the intracellular content of actin. Error bars, S.D. *Pr0.05; ***Pr0.001
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cells, indicating that YYY239/240/317 are required for
the inhibitory effects of p66Shc on the signaling pathways
that control Vav activation and actin reorganization in
B-cells.
In agreement with the requirement for YYY239/240/317
phosphorylation in the regulation of CXCR4/CXCR5 signaling
by p66Shc, p66Shc was found to be phosphorylated on
tyrosine in response to CXCL12/CXCL13 (Figure 6e).
Figure 6 Inhibition of CXCR4 and CXCR5 signaling by p66Shc requires tyrosine phosphorylation of its CH1 domain. (a) Immunoblot analysis with anti-phospho-Vav
antibody of postnuclear supernatants from ctr, p66 and p663F MEC transfectants either unstimulated or stimulated for 1 min with 100 ng/ml CXCL12 or 200 ng/ml CXCL13.
A control anti-actin immunoblot of the stripped filter is shown below. The migration of molecular mass markers is indicated. (b, top) Confocal microscopic analysis of Vav
phosphorylation in the ctr, p66 and p663F MEC transfectants plated on slides coated with 10 mg/ml rhICAM-1/Fc and stimulated for 2 min with either 100 ng/ml CXCL12 or
200 ng/ml CXCL13. Slides were then labeled with anti-phospho-Vav and anti-Vav antibodies. Median optical sections are shown. Size bar, 5mm. (b, bottom) Quantification of
Vav phosphorylation on four different wide-field images from three independent experiments presented as the mean fluorescence intensity (MFI) of phospho-Vav staining in
stimulated versus unstimulated samples, quantitated using ImageJ software and normalized to the intracellular content of Vav. Error bars, S.D. *Pr0.05; **Pr0.01;
***Pr0.001. (c) Immunoblot analysis with anti-phospho-Syk antibody of postnuclear supernatants from ctr, p66 and p663F MEC transfectants either unstimulated or
stimulated for 1 min with 100 ng/ml CXCL12 or 200 ng/ml CXCL13. A control anti-actin immunoblot of the stripped filter is shown below. The same filter was probed with anti-
phospho-Btk antibody. The migration of molecular mass markers is indicated. (d) Immunofluorescence analysis of ctr, p66 and p663F MEC cells transiently transfected to
express a PH-GFP fusion, immobilized 24 h after transfection on slides coated with 10mg/ml rhICAM-1/Fc either unstimulated or stimulated with 100 ng/ml CXCL12 or 200 ng/ml
CXCL13 and labeled with Phalloidin-TRITC (red) and anti-GFP antibodies (green). Median optical sections are shown. Size bar, 5 mm. (e) Immunoblot analysis with
anti-phosphotyrosine antibodies of p66Shc-specific immunoprecipitates from lysates of p66 and p663F MEC cells either unstimulated or activated for 1 min with 500 ng/ml
CXCL12 or 1.25 mg/ml CXCL13. The stripped filter was reprobed with anti-Shc antibodies
p66Shc inhibits B-cell chemotaxis
L Patrussi et al
8
Cell Death and Disease
p66Shc recruits SHIP-1 and SHP-1 to CXCR4 and
CXCR5. The results obtained with the p66Shc mutants
suggests that p66Shc may interfere with CXCR4/CXCR5
coupling to Vav by acting as an adaptor to recruit negative
regulators of the TK-dependent or the PI3-K-dependent
pathways triggered by these receptors. To address this
issue, p66Shc/p66Shc3F was immunoprecipitated from MEC
transfectants expressing the GFP-tagged proteins and
probed for the presence of CXCR4 and CXCR5. Both
receptors were found to be engaged in a constitutive
interaction with p66Shc as well as p66Shc3F (Figure 7a).
Accordingly, immunofluorescence analysis showed that a
proportion of p66Shc, as well as p66Shc3F, is localized at
the plasma membrane under basal conditions (Figure 7b).
Figure 7 p66Shc recruits the phosphatases SHIP-1 and SHP-1 to CXCR4 and CXCR5. (a) Immunoblot analysis with anti-CXCR4, CXCR5, SHIP-1 or SHP-1 antibodies of
GFP-specific immunoprecipitates from lysates of the GFP-p66 and GFP-p663F MEC transfectants either unstimulated or stimulated for 1 min with 100 ng/ml CXCL12 or
200 ng/ml CXCL13. Control anti-GFP immunoblots of the stripped filters are shown below. The migration of molecular mass markers is indicated. (b) Confocal microscopic
analysis of SHIP-1 in the ctr, p66 and p663F MEC transfectants plated on slides coated with 10mg/ml rhICAM-1/Fc and stimulated for 1 min with either 100 ng/ml CXCL12 or
200 ng/ml CXCL13. Slides were then labeled with anti-SHIP-1 antibody. Median optical sections are shown. Size bar, 5mm. (c) Confocal microscopic analysis of GFP and
SHIP-1 in the GFP-p66 and GFP-p663F MEC transfectants plated on slides coated with 10mg/ml rhICAM-1/Fc and stimulated for 1 min with either 100 ng/ml CXCL12 or
200 ng/ml CXCL13. Slides were then labeled with anti-SHIP-1 antibody. Median optical sections are shown. Size bar, 5 mm
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PIP3 is rapidly dephosphorylated by the phosphatase SHIP-1
(SH2 domain-containing inositol 5’-phosphatase-1)23 that
negatively regulates CXCR4-dependent B-cell chemotaxis.24
Co-immunoprecipitation experiments showed a basal SHIP-1
association with p66Shc that was strongly enhanced in
response to CXCL12/CXCL13 (Figure 7a). A substantial
proportion of SHIP-1 was observed at the plasma membrane
under basal conditions in p66Shc-expressing MEC cells,
with a significant colocalization with GFP-tagged p66Shc
(Figure 7c). Although a basal association of SHIP-1
with p66Shc3F was also observed, it was not enhanced by
chemokine treatment (Figure 7a). Moreover, SHIP-1 was
largely cytosolic in the absence of stimulation in p66Shc3F-
expressing cells, and a substantial cytosolic pool was also
observed following chemokine treatment (Figure 7b). Hence,
p66Shc inhibits PI-3K signaling by recruiting SHIP-1 to
CXCR4/CXCR5 through its CH1 domain.
The fact that p66Shc negatively regulates the TK cascade
triggered by CXCR4/CXCR5 suggests that it may counteract
TKs by recruiting tyrosine phosphatases to these receptors.
The tyrosine phosphatase SHP-1 (Src homology phospha-
tase-1) is implicated in negative signaling by a variety of
receptors in hematopoietic cells.25 Probing p66Shc-specific
immunoprecipitates revealed the presence of SHP-1 under
basal conditions that was enhanced in response to CXCL12/
CXCL13 (Figure 7a). A basal interaction, which however did
not increase in response to chemokine stimulation, was
observed in cells expressing p66Shc3F (Figure 7a), indicating
that p66Shc inhibition of TK signaling involves SHP-1
recruitment to CXCR4/CXCR5 through YYY239/240/Y317.
Discussion
Despite our limited mechanistic understanding of CXCR4 and
CXCR5 signaling in B-cells, several signaling mediators have
been identified. The integrin high-affinity conformational shift
triggered by CXCR4 involves Ras-proximate-1 (Rap1), protein
tyrosine kinase 2 (Pyk2) and focal adhesion kinase (FAK)
activation.26Moreover, CXCR4 triggers the Lyn-, Syk- and PI3-
K-dependent activation of Rho GTPases through a cascade
involving Btk and phospholipase C, g (PLCg).27 Less is known
about CXCR5, although the signaling mediators identified in
this pathway, such as Rap1, PI3-K and Pyk2,27–29 suggest that
it may recapitulate the CXCR4 pathway. The role of the
adaptors that act as scaffolds to promote the activation and
function of these molecules in the pathways triggered by AgRs
has been addressed only for very few instances. Both SLP-76
(SH2 domain-containing leukocyte protein of 76kDa), which
controls TCR-dependent Rap1 activation,30 and LAT, which
couples the TCR to Vav and Rho GTPases,31 are dispensable
for CXCR4 signaling in T cells,32,33 suggesting that different
adaptors may be implicated in the assembly of the chemokine
receptor-associated signalosome. However, SLP-76 has been
recently identified as a common target of TCR and CXCR4 in
the generation of signaling microclusters;34 moreover, the role
for SLP-76 in LFA-1-dependent T-cell adhesion has been
re-evaluated in the setting of shear flow.35TheadaptorsCrkLand
Cbl-b are recruited in a multimolecular complex in response to
CXCR4 engagement in a pre-B lymphoma line,36 but their
role in B-cell migration has not been directly addressed.
The results presented here contribute to filling this gap by
identifying p66Shc, which participates as a negative regulator
in B-cell receptor (BCR) signaling,37 as a central component
of the pathways that couple CXCR4/CXCR5 to integrin
activation and actin dynamics in B-cells. Although the
physiological levels of p66Shc expression in primary B-cells
are relatively low, they are clearly sufficient to tune down the
responses triggered by these receptors, as highlighted by
their significant enhancement in p66Shc / B-cells.
p66Shc appears to function downstream of Gi activation at
the early steps of CXCR4/CXCR5 signaling in the pathways
that couple Lyn and PI3-K to Vav, but not in the Gi-
independent Jak pathway, as supported by the exacerbation
of the chemotaxis defects in p66Shc-expressing B-cells when
treated with either PTX or PP2 or wortmannin, but not AG490.
A comparison of Lyn, Syk and Btk activation in B-cells differing
in p66Shc expression maps p66Shc downstream of Lyn. Lyn
activation is believed to occur through its recruitment to lipid
rafts with the activated chemokine receptors.38 That p66Shc
does not affect Lyn activation indicates that its constitutive
interaction with CXCR4/CXCR5 does not impinge on either
their raft clustering or their ability to recruit Lyn. A mechanism
by which p66Shc attenuates TK signaling downstream of Lyn
can be proposed based on our finding that it interacts with
SHP-1 that binds to and dephosphorylates Syk in B-cells.39
This does not rule out the possibility of a transdominant
inhibition of p52Shc that participates in TCR transactivation by
CXCR4 in T cells.15 Nevertheless, this possibility appears
unlikely, as this inhibitory function of p66Shc relies on S36
phosphorylation,12 whereas the data presented here indicate
that this molecular determinant is dispensable for the negative
regulation of CXCR4/CXCR5 signaling by p66Shc in B-cells.
Inhibition of phosphoinositide signaling by p66Shc is likely
to contribute to the Vav activation defect in response to
CXCR4/CXCR5, as both Btk and Vav are provided of a
phosphoinositide-binding domain.21 The ability of p66Shc to
reduce phosphoinositide accumulation may moreover con-
tribute to the impairment of inside-out signaling to integrins by
affecting the assembly of the complex that promotes Rap1
activation that in B-cells includes the PH domain-containing
adaptor Src kinase-associated phosphoprotein-homology
(SKAP-hom).40 Although a modulation of PI3-K activity by
p66Shc cannot be ruled out, inhibition of CXCR4/CXCR5-
dependent phosphoinositide accumulation by p66Shc stems,
at least in part, from its ability to enhance SHIP-1 recruitment
to the plasma membrane, similar to what we have described
for FceRI signaling in mast cells.41 SHIP-1 associates with
p52Shc through a bidentate interaction involving binding of
the SHIP-1 SH2 domain to phosphorylated YYY239/240/317,
as well as binding of the phosphorylated SHIP-1 NPXY motif
to the Shc PTB domain.42,43 The basal association of p66Shc
with CXCR4/CXCR5 suggests that p66Shc could recruit an
initial SHIP-1 pool to the receptors in the absence of
stimulation, as supported by the constitutive membrane
localization of SHIP-1 in p66Shc-expressing cells. Following
chemokine binding, CXCR4/CXCR5 could promote p66Shc
and SHIP-1 phosphorylation, thereby stabilizing the p66Shc-
SHIP-1 complex at the plasma membrane, as supported by
the chemokine-dependent enhancement in SHIP-1 binding to
p66Shc, but not p66Shc3F. It is noteworthy that SHIP-1 /
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B-cells display adhesion and chemotaxis defects similar to the
ones described here for p66Shc / B-cells,24 supporting the
notion that p66Shc negatively regulates these processes
through SHIP-1.
The ability of p66Shc to generate ROS appears in contrast
to its inhibitory effects on B-cell adhesion and migration, as
these processes are regulated by oxidants. During EC
migration, the NADPHox (nicotinamide adenine dinucleotide
phosphate-oxidase) subunits NOX2 and p47phox are targeted
to the leading edge where they generate superoxide44,45 that
promotes cell migration through the oxidation-dependent
inhibition of protein phosphatases.46 ROS also promote
leukocyte adhesion to ECs by enhancing ICAM-1 and
P-selectin expression,47,48 and by inducing a turnover of EC
junction proteins.49 p66Shc promotes ROS accumulation by
both inhibiting forkhead transcription factors that control the
expression of anti-oxidant enzymes50 and interrupting the
mitochondrial respiratory chain.51 Subcellular compartmenta-
lization of ROS generation has emerged as an important
feature of ROS signaling.52 We can hypothesize that p66Shc
may generate ROS at locations that are not relevant to the
signaling pathways that mediate CXCR4/CXCR5-dependent
B-cell migration. In support of this notion, NADPHox inhibition
did not affect the ability of p66Shc to increase intracellular
ROS in T cells (A Nuccitelli and CT Baldari, unpublished). It is
noteworthy that p66Shc mediates anoikis in fibroblasts by
promoting RhoA activation and focal adhesion formation53
and promotes VEGF-dependent ROS production in ECs by
activating Rac1 and NAPDHox.54 Hence, the effects of
p66Shc on chemotaxis and the role of its pro-oxidant activities
in this process appear to be cell type-specific.
We have recently shown that p66Shc modulates the
expression of receptors that control B-cell entry (CCR7) and
egress (sphingosine-1-phosphate receptor 1 (S1P1)) through
its pro-oxidant activity,14 suggesting its implication in their
trafficking to SLOs. The results presented here show that
p66Shc can additionally participate in B-cell homing by
attenuating signaling to the actin cytoskeleton by CXCR4/
CXCR5, acting as an adaptor to recruit negative regulators.
Collectively, the data identify p66Shc as a multifunctional
regulator of B-cell trafficking.
Materials and Methods
Cell lines, plasmids, antibodies and reagents. A panel of MEC-1
B-cell stable transfectants expressing either p66Shc (p66) or the p66ShcSA
(p66SA) or p66ShcQQ (p66QQ) point mutants, as well as an empty vector
transfectant (ctr), were previously described.14 A MEC-1 transfectant was
generated using a construct encoding a p66Shc point mutant lacking the three
phoshorylatable tyrosine residues (YYY239/240/317) in the CH1 domain
(p66Shc3F).55 The cDNAs encoding p66Shc and p66Shc3F were cloned into
pEGFP-C3 (Invitrogen, Carlsbad, CA, USA) and stably transfected into MEC-1
cells as described previously.14 A vector encoding the GFP-tagged Akt PH
domain56 was transiently transfected into the stable control, p66 and p663F
transfectants. Murine OP957 and human HS-558 stromal cells were used for
pseudoemperipolesis experiments.
Phosphospecific antibodies recognizing the phosphorylated active forms of Syk,
Btk and Lyn were from Cell Signaling Technology (Beverly, MA, USA) and
anti-phospho-Vav was from Biosource (Camarillo, CA, USA). Anti-Erk2, anti-SHIP-1
and anti-Shc antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA,
USA), anti-actin was from Chemicon Int. (Temecula, CA, USA), and anti-
phosphotyrosine, anti-Vav and anti-Shc antibodies were from Millipore (Billerica,
MA, USA). Anti-CXCR5 and anti-SHP-1 antibodies were from Abcam (Cambridge,
UK), anti-CXCR4 polyclonal antibodies were from Sigma-Aldrich (St. Louis, MO,
USA), anti-CXCR4 mAbs were from Abnova (Aachen, Germany), anti-GFP
polyclonal and mAbs were from Invitrogen. Anti-CXCR4 (12G5) antibodies were
kindly provided by J Hoxie, Leukosite Inc. and the MRC AIDS Reagent Project
(Cambridge, MA, USA). p66Shc was immunoprecipitated using a rabbit polyclonal
antiserum raised against a CH2-glutathione S-transferase (GST) fusion protein.59
Secondary peroxidase-labeled antibodies were from GE Healthcare (Fairfield, CT,
USA). Anti-CD11a, anti-human CD3 and CD19, anti-mouse CD3 and CD22 and
secondary fluorochrome-labeled antibodies were from eBioscience (San Diego, CA,
USA); anti-GFP and Alexa Fluor 488- and 555-labeled secondary antibodies were
from Invitrogen (Leek, The Netherlands). Human and mouse CXCL12 and CXCL13,
FN, AG490, PP2, AMD3100, IBMX, f-MLP and TRITC-labeled Phalloidin were
purchased from Sigma-Aldrich. PTX was purchased from Sigma-Aldrich. rhICAM-1/Fc
was purchased from R&D Systems (Minneapolis, MN, USA). The chemilumines-
cence detection kit was from Pierce (Rockford, IL, USA). DiO and Dil fluorescent
dyes were purchased from Molecular Probes (Invitrogen).
Mice. p66Shc / /129 mice (p66Shc / ) have been previously described.59
Analyses were performed on age- and sex-matched 2–9-month-old wild-type 129
mice (wt). All experiments were carried out in agreement with the Guiding
Principles for Research Involving Animals and Human Beings and approved by the
local ethics committee. Experiments were carried out on spleen, lymph nodes
and bone marrow suspensions, or splenic B-cells negatively purified by
immunomagnetic sorting using the Dynabeads Mouse CD43 Negative Isolation
Kit (Invitrogen) (485% purity).
Activations and immunoprecipitations. Cells were starved for 2 h in
RPMI/1% BSA. Activations with CXCL12 or CXCL13 (10–500 ng/ml, 0.1–1.25mg/ml,
respectively, depending on cell concentration) were carried out at 371C in
RPMI/1% BSA. Cells were lysed in 1% Triton X-100 in 20 mM Tris-HCl, pH 8,
150 mM NaCl (in the presence of protease inhibitor cocktail, Invitrogen), resolved
by SDS-PAGE and transferred to nitrocellulose (Whatman, GE Healthcare).
Alternatively, postnuclear supernatants from 2.5–5 107 cells/sample were
immunoprecipitated using the appropriate antibodies and protein A-Sepharose
(GE Healthcare).
Flow cytometry and chemotaxis assay. Transwell migration assays
were carried out as described previously.15 Migrated cells were counted by flow
cytometry. Mouse cells were stained with anti-CD3/anti-CD22 antibodies before
analysis. The migration index was calculated by determining the ratio of migrated
cells in treated versus untreated samples.
Adhesion assay. The 48-well plates were coated o/n at 41C with either
10mg/ml FN or 10mg/ml rhICAM-1/Fc, washed with PBS and incubated for 30 min
at 371C with RPMI/1% BSA. Then, 2 105 cells/well serum-starved B-cells were
added. The plates were incubated at 371C for 10 min, then added with 100 ng/ml
CXCL12 or 200 ng/ml CXCL13 for further 10 min. Cells that had not adhered
(recovered in medium and washes) were resuspended in 0.2 ml RPMI. Cells that
remained adherent after 3 washes were recovered by 1-min incubation with
trypsin/EDTA, immediately added with RPMI-10% BCS, washed and resuspended
in 0.2 ml RPMI. Cells were counted by flow cytometry. Mouse cells were stained
with anti-CD3/CD22 antibodies before flow cytometry. The percentage of adherent
cells was calculated as follows:
no:adherent
no: total
100
where ‘total’ is the sum of adherent and nonadherent cells/well.
Pseudoemperipolesis assay. Stromal cells were seeded on 48-well
plates (1.5 105 cells/well) in RPMI/10% BCS and cultured to confluence. Then,
2 105 cells/well serum-starved B-cells were added. Plates were incubated at
371C for 10 min, then added with 100 ng/ml CXCL12 or 200 ng/ml CXCL13 for
40 min. Wells were vigorously washed three times with RPMI and the cells that
had not adhered (recovered in medium and washes) were resuspended in 0.2 ml
medium. The stromal cell layer containing migrated cells was trypsinized as
described above and cells were suspended in 0.2 ml medium. Cells were counted
by flow cytometry. All samples were stained with anti-CD19 (human cells) or anti-
CD3/CD22 (mouse cells) antibodies before flow cytometry to exclude stromal cells.
The percentage of migrated cells was calculated as above.
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Immunofluorescence, confocal microscopy and polarization
assay. Diagnostic microscope slides were coated with FN or rhICAM-1/Fc and
cells (1 105/sample) were allowed to adhere for 5 min before stimulation for
2–5 min with 100 ng/ml CXCL12 or 200 ng/ml CXCL13. Cells transiently
transfected with the PH-GFP-expressing vector were used 24 h after transfection.
Slides were immediately fixed in 4% paraformaldehyde at RT for 20 min as
previously described.60 For SHIP-1 and SHP-1 staining, cells were plated for
15 min on polylysine-coated slides and then stimulated as above. Following
fixation, samples were washed 5 min in PBS and incubated with primary
antibodies or TRITC-labeled Phalloidin o/n at 41C or 1 h at RT. After washing in
PBS, samples were incubated for 1 h at RT with Alexa Fluor 488- and 555-labeled
secondary antibodies.
Confocal microscopy was carried out on a Zeiss LSM700 (Carl Zeiss, Jena,
Germany) using a  63 objective. Images to quantify were acquired with pinholes
opened to obtain 0.8mm-thick sections. Detectors were set to detect an optimal
signal below the saturation limits. Images were processed with Zen 2009 image
software (Carl Zeiss) and analyses were performed using ImageJ software
(downloaded from http://www.embl-heidelberg.de/eamnet/).
For the polarization assay, slides were stained with TRITC-labeled Phalloidin and
anti-actin mAb, four different wide-field images/well (at least 25 cells/field) were
taken and the percentage of polarized cells (with protrusions or with irregular
morphology; see representative images in Figure 1a) against total cells was
calculated. In the same images, mean fluorescence intensity (MFI) of Phalloidin and
actin staining was quantitated using ImageJ software. For each the Phalloidin
staining was normalized to the actin staining.
RNA purification and real-time PCR. Total RNA was extracted from
MEC transfectants or mouse B lymphocytes and retrotranscribed as previously
described.37 Real-time PCR was performed in triplicate on 96-well optical PCR
plates (Sarstedt AG, Nu¨mbrecht, Germany) as previously described14 using
SSoFast EvaGreen SuperMix (Bio-Rad Laboratories Inc., Hercules, CA, USA) and
a CFX96 Real-Time system (Bio-Rad Laboratories, Waltham, MA, USA).
Transcript levels were normalized to the housekeeping gene HPRT1.
Statistical analysis. Mean values, S.D. and Student’s t-test (unpaired) were
calculated using Microsoft Excel (Redmont, WA, USA). A Po0.05 was considered
statistically significant.
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